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Abstract
The European Group generally agrees with the American guidelines on the issue of the indications for additional
surgery in patients with recurrence of medullary thyroid cancer. The discussions have been focused mainly on the
postoperative follow-up, where some European experts feel that a postoperative calcitonin-stimulating test is of
some importance in assigning the patient to the “Cured” or “Non-cured” group immediately after surgery. A part of
the European group feels that a negative calcitonin-stimulating test might lead to a less intensive follow-up in the
late follow-up of these patients.
Initial evaluation and treatment of postoperative
patients
Recommendation 73
MTC serum tumor markers (Ct and CEA) should be
measured 2–3 months postoperatively. Grade: B
In the US guidelines it is stated that a stimulated Ct is
not considered essential in the follow-up of the patient
after surgery. The question that rose from the European
panel was about its potential role in the postoperative
course.
We should underline that some European experts
believe that the role of stimulated Ct in the evaluation
of complete success of surgery is essential for both the
diagnosis and the follow-up of patients with medullary
thyroid cancer. The stimulation can be performed with
either pentagastrin (not easily available anymore also in
Europe) or calcium (this test has been proved to be as
effective as the pentagastrin test [1,2]).
When both the basal and the stimulated serum Ct are
undetectable the patient is in complete biochemical remis-
sion and has about a 3% chance of biochemical recurrent
disease during follow-up [3]. A negative postoperative
stimulation test (defined by a Ct<10 pg/ml equal to <10
ng/L, as defined by Machens), is very restrictive and iden-
tifies patients that might undergo a less aggressive follow-
up.
An European expert proposes a less restrictive cut-off
of 30 pg/ml[ng/L]. The European board does not give
any comment to this proposal.
Recommendation 74
When the postoperative basal serum Ct is undetectable
(along with an undetectable stimulated serum Ct if per-
formed, although the majority of the Task Force felt it was
unnecessary), the risk of persistent or recurrent residual dis-
ease is low, and other tests or imaging techniques are not
immediately required and the patient may enter into long-
term follow-up. A neck US may be considered to establish
a baseline. Grade: E Recommendation
The European panel agrees on this recommendation. A
short comment is made about the role of a postoperative
“baseline” neck US in the case of a patient who is defined
as “disease free” by serum Ct. Is it necessary to mention it
in the guidelines, considering that it might be misinter-
preted when performed by a non-expert radiologist?
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Testing and treatment of patients with detectable Ct
Recommendation 75
Postoperative MTC patients with detectable serum Ct
levels <150 pg/mL should be evaluated with neck US.
Grade: B Recommendation
Recommendation 76
In addition to neck US, postoperative MTC patients with
detectable serum Ct levels that are <150 pg/mL may be
considered for additional imaging to serve as baseline
examinations for future comparison even though these stu-
dies are usually negative. Alternatively, this additional ima-
ging can be deferred and subsequently implemented should
the serum Ct rise over time. Grade: C Recommendation
It is unlikely to observe metastatic disease in patients
with Ct < 150 pg/ml[ng/L]. The panelists agree with the
American guidelines in defining the cut-off for further
surgery only when there is morphologic evidence of meta-
static disease, regardless of the Ct level. When surgery is
indicated, the data available from the literature agree on the
extreme rarity of a biochemical cure obtained after a
second (or third) operation. Nevertheless, the reports also
demonstrates that the overall prognosis might be improved
in terms of survival.
Recommendation 79
In addition to neck US, postoperative MTC patients with
serum Ct levels ≥150 pg/mL should undergo additional
imaging techniques to evaluate for distant metastases.
Grade: Recommendation B
The European panel agrees on this recommendation
without further comments.
Initial evaluation and treatment of postoperative
patients: role of invasive methods of staging
Recommendation 86
We do not recommend the routine use empiric liver or
lung biopsies, hepatic vein sampling, systemic vascular
sampling, or hepatic angiography prior to re-operation.
These diagnostic procedures should be used sparingly, if
at all. Grade: D Recommendation
The European panel strongly agrees in the contraindi-
cation of these invasive and potentially morbid proce-
dures.
Patients with detectable serum Ct
postoperatively, with negative imaging
Recommendation 90
Patients with detectable basal serum Ct levels postopera-
tively with negative imaging should have the basal Ct and
CEA levels obtained approximately every 6 months initi-
ally to determine the DTs. Ongoing follow-up of these
tumor markers and physical examination should occur at
one fourth the shortest DT or annually, whichever is more
frequent (i.e., follow the patient every 6 months if the
shortest DT is 24 months). Grade: B Recommendation
The European panel agrees on this recommendation
without further comments.
Recommendation 91
In patients with detectable basal serum Ct levels post-
operatively with negative imaging, if the Ct or CEA rises
substantially since the previous anatomic imaging eva-
luation, then a neck US should be performed. The Ct ele-
vation required to trigger this action typically depends on
the basal serum Ct and the clinical situation, but eleva-
tion by more than 20% to 100% may prompt this
evaluation. If the serum Ct is >150 pg/ml then systemic
imaging should be repeated as well. Grade: C Recom-
mendation
A few European experts comment that citing cut-offs
in these cases (last sentence) might be redundant, since
imaging will always be indicated in such patients, regard-
less of any threshold.
Long-term follow-up of patients in complete
biochemical cure
Recommendation 114
Long-term biochemical monitoring for patients with
MTC who achieve a complete biochemical cure should
be performed. Grade: B Recommendation
Recommendation 115
Long-term biochemical monitoring for MTC patients who
achieve a complete biochemical cure should include annual
measurement of serum Ct. Grade: C Recommendation
The European experts take into consideration the possi-
bility of a less regular follow-up after 10 years of “bio-
chemical cure” of the disease, after the results described
by Machens et al. [3] (JCEM 2005) who reported their
incidence of recurrence in a range between 0.7-7.5 years.
A new (and definitive?) stimulation test after 10 years is
also proposed aiming at excluding the patients with a
negative test from further tests.
Patients with detectable serum Ct
postoperatively, with negative imaging: long-
term follow-up
Recommendation 116
Patients with persistent MTC should be monitored by
measuring Ct and CEA levels, along with history and
physical examinations. The timing of follow-up anatomic
imaging may be based on the relative stability of these
tests, presence or absence of symptoms, and the location
of known or likely sites of metastatic deposits. Grade: C
Recommendation
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Recommendation 117
Patients with detectable basal serum Ct levels postopera-
tively should have the basal Ct and CEA levels obtained
approximately every 6 months to determine their DTs.
Ongoing follow-up of these tumor markers and physical
examination should occur at one fourth the shortest DT
or annually, whichever is more frequent (i.e., follow
patient every 6 months if the shortest DT is 24 months).
Grade: C Recommendation
Recommendation 118
In patients with detectable basal serum Ct levels post-
operatively, if the Ct or CEA rises substantially since the
previous anatomic imaging evaluation, then a neck US
should be performed. The Ct elevation required to trigger
this action typically depends on the basal serum Ct and
the clinical situation, but elevation by more than 20–
100% may prompt this evaluation. If the serum Ct is
>150 pg=mL then systemic imaging should be repeated
as well. Grade: C Recommendation
See comments for Recommendations 90 and 91.
Follow-up of patients without MTC at
thyroidectomy
Recommendation 119
After prophylactic thyroidectomy demonstrates no evidence
of MTC, the risk of developing MTC is low, and the opti-
mal follow-up for these patients is uncertain. Annual
measurement of basal serum Ct without measurement of
CEA should be considered. Less frequent testing may be
considered if there is no evidence of disease after pro-
longed follow-up. Grade: C Recommendation
No further comments from the European panel.
Role of stimulated Ct testing in the opinion of the
American Experts
Recommendation 120
Stimulated serum Ct testing may detect low levels of resi-
dual disease despite undetectable basal Ct values. Such
minimal disease is currently unlikely to be able to be
localized or treated, and therefore this follow-up testing
is not recommended (agreement amongst the Task Force
was not unanimous). Grade: D Recommendation
The comment should underline, again, how differently
the importance of the stimulation test is perceived by
the Europeans; it is also important to notice how among
the experts in the American panel there are also discor-
dant opinions.
In European countries, stimulated Ct testing is com-
monly used both prior to and after the surgical treat-
ment of medullary thyroid cancer, and is interpreted as
a necessary tool by the majority of the clinicians
involved in the management of the tumor.
Management of CEA-positive but Ct-negative
patients
Recommendation 121
Elevated CEA levels that are out of proportion to the
serum Ct may occur from several causes, including some
unrelated to MTC, which should be considered and eval-
uated as appropriate based on clinical judgment. Grade:
C Recommendation
No further comments are made from the European
panelists.
Conclusions
Postoperative follow up in patients showing no evident
residual disease - cut-offs for imaging/ intervention
The European experts generally agree with the Ameri-
can guidelines for what concerns the indications and limits
for additional interventions in patients who underwent
surgery for medullary thyroid cancer.
The only different issue appears to be in the follow-up,
and specifically in the role of a stimulating test that is felt
important for the Europeans. A negative stimulation test
might select those patients that might undergo a less
aggressive follow-up because of their unlikely recurrence.
No other important issues have been discussed.
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